Danish/Australian co-operation to improve TB (tuberculosis) diagnosis
This article was originally published in Clinica
The Danish State Serum Institute (SSI) and the Australian biotechnology company Cellestis, have entered into an agreement to jointly develop tuberculosis diagnosis technology. The agreement will grant the Melbourne-based company exclusive rights to SSI's TB specific protein, to use in its QuantiFERON diagnostic technology.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.